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Abstract
Since the 1990s, when it was demonstrated by Hammel and others that liver fibrosis is reversible, researchers and physicians
actively search for new antifibrotic therapies. In recent years, knowledge of liver fibrosis pathophysiology has greatly advanced
and new cellular and molecular mechanisms were described. The cells that determine extracellular matrix components distribu-
tion are myofibroblasts, but their origin is diverse. They can be activated hepatic stellate cells (HSCs), portal fibroblasts (PF), or
circulating mesenchymal stem cells of the bone marrow. Among large number of substrates to inhibit activation, to inhibit
proliferation of myofibroblasts, and to induce their apoptosis we, chose curcumin and gliotoxin. Primarily, in the current work,
we optimized the explantation culture method for isolation of hepatic myofibroblasts and received two different cultures—
myofibroblasts of HSC and PF origin. Exposition of 50 μM curcumin and 0.1 μM gliotoxin was the most optimal; we observed
suppression of hepatic myofibroblast activation and inhibition of their proliferation. These results extend the current knowledge
of the cells within the liver fibrogenic populations and prove inhibitory influence of biologically active substances (curcumin and
gliotoxin) on portal myofibroblasts.
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1 Introduction
Liver fibrosis is an extensive substitution of extracellular ma-
trix (ECM) in response to chronic injury [1]. In comparison to
acute liver injury, when hepatocytes and cholangiocytes retain
their possibility to proliferate and replace damaged cells, in the
case of chronic liver diseases, the resource of hepatic paren-
chymal cells to regenerate fails and then starts the changes in
ECM deposition to replace the damaged region or to isolate it
from other intact areas that manifests like liver fibrogenesis.
The nature of injury agent determines the cells, which respond
to damage, and diverse types of ECM distribution: in chronic
viral hepatitis and chronic cholestatic disorders—around por-
tal tracts, and in alcohol-induced liver disease—in pericentral
and perisinusoidal areas [2]. In recent years, knowledge of
liver fibrosis pathophysiology has greatly advanced and new
cellular and molecular mechanisms were described.
Being resident mesenchymal cells of the liver, hepatic stellate
cells (HSCs) and portal fibroblasts (PF) [3] are one of the first
cells that activate, transdifferentiate into myofibroblasts, and ac-
quire fibrogenic potential in response to liver injury [4–9].
In the normal liver, HSCs are located in the perisinusoidal
space of Disse and being a quiescent cell population, they are
the major storage of vitamin A [10]. Under chronic injury,
HSCs activate and transdifferentiate into myofibroblast-like
cells with contractile, proinflammatory, and fibrogenic prop-
erties [11, 12]. This could be followed by the changes of HSC
phenotype: whereas quiescent HSCs express markers of adi-
pocytes (PPAR-γ, SREBP-1c, and leptin), activated HSCs
express myogenic markers (α-smooth muscle actin (α-
SMA), c-myb, and myocyte enhancer factor-2) [4]. Due to
their features, they had been thought for a long time as a main
Bcauser^ of liver fibrosis and cirrhosis [13]. Briefly, the dam-
aged hepatocytes and stellate macrophages of the liver
(Kuppfer cells) release reactive oxygen species and mediators
that stimulate the migration of white blood inflammatory cells
to the damaged region [14–16]. Inflammatory cells in their
turn activate HSC that also produce chemokines to modulate
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the activity of lymphocytes [17]. Thus, appears a vicious path-
ological circle where every cell type stimulates each other
[18]. Being activated, HSCs become a source of inflammatory
mediators, transdifferentiate into myofibroblasts, acquire
fibrogenic potential, and start to produce components of
ECM [19]. Among ECM components synthesized by HSC
are collagen fibers (I, III, and IV) and then fibronectin,
undulin, elastin, laminin, hyaluronan, and proteoglycans. At
the same time, HSCs also produce matrix metalloproteinases
(MMPs) [20] and their inhibitors (tissue inhibitors of matrix
metalloproteinases, TIMPs), which regulate ECM distribu-
tion. Thus, ECM accumulation is a result of both increased
synthesis and decreased degradation of ECM [21].
In the recent years, it was shown that not only HSC possess
fibrogenic activity, also portal fibroblasts (PF) under influence
of damaged epithelial cells can transdifferentiate into
myofibroblasts and initiate collagen deposition around portal
tracts [22]. Interestingly, these cells were first described in
1961 by Carruthers and colleagues, who studied the rat portal
tracts after bile duct ligation [23, 24], but the cells were for-
gotten then and only in last years they became under great
interest again. Nowadays, the term PF defines fibroblasts, lo-
calized in the portal area and not originated from HSC [25].
Normally, PF can be found around the portal vein and they
maintain integrity of the portal tract [26]. PF regulate
cholangiocyte proliferation, create peribiliary stem cells niche
by deposition of elastin and other components of microfibrils;
they also maintain stability of the portal tract structures under
increased ductal pressure [25, 27]. New interesting angiogenic
property of PF was described in 2015—portal myofibroblasts
overexpress COL15A1, the α1 chains of collagen XV, nor-
mally present in trace amounts in portal and periportal areas,
but whose significant quantities are detected in the case of
hepatocellular carcinoma and pathological angiogenesis dur-
ing liver fibrosis [28]. Due to the localization, PF react first to
the chronic cholestatic liver diseases and biliary obstruction
[29] and become the main source of connective tissue in the
case of biliary cirrhosis [26, 30]. HSC will be also involved in
fibrogenesis, but later with disease progression [27, 31, 32].
Along with these two types of myofibroblasts (activated HSC
and PF), some authors distinguish a third one—myofibroblasts
with intermediate phenotype and unknown origin, probably cir-
culatingmesenchymal stem cells of the bonemarrow [33–35]. In
some of the experimental works, it was shown the contribution of
smooth muscle cells of vascular tunica media [36], second layer
cells around the centrilobular veins [37], and capsular fibroblasts
in the Glisson’s capsule [38] or even epithelial-mesenchymal
transition [39], but it still remains controversial.
As far as myofibroblasts could be of different origins, there is
a question to distinguish them. The generally accepted main
marker of myofibroblasts is the presence in their cytoplasm of
α-SMA. To determine the origin of the myofibroblasts (HSC,
PF, or bone marrow cells), we can turn to their antigenic
properties. The resident HSC cells are characterized by expres-
sion of desmin and glial fibrillary acidic protein (GFAP)—
markers, expressed even after HSC transdifferentiation and
distinguishing HSC myofibroblasts from other types [19].
Generally, the regulation of cellular growth and function is under
transcription factor control. Such a transcription factor in HSC is
nuclear factor κB (NF-κB), whose increased levels and nuclear
translocation are associated with HSC activation. [40–42]. HSC
are also characterized by the absence of hematopoietic markers
(CD45, CD34) and Thy-1 (glycophosphatidylinositol-associated
glycoprotein on the outer cell membrane that has previously been
detected in fibroblasts of certain organs, CD90). Myofibroblasts,
resulting from epithelial-mesenchymal transformation, are char-
acterized by the absence of CD45 expression and production of
markers of hepatocytes (Albumin, Alb) and cholangiocytes
(cytokeratin-19, CK-19) [39]. The cells from circulating bone
marrow cells present CD45+/Coll1+ myofibroblasts. PF differ
from HSC by the following features: they can express elastin
and Thy-1, do not accumulate retinoids, and do not express des-
min, CD146, or neural markers (GFAP) [43].
As far as it was shown that liver fibrosis is reversible [44],
the search for the ways of myofibroblast fibrogenic potential
regulation is under great interest [45]. However, to study the
phenotype, features, and activation of the myofibroblasts, it is
better to isolate these cells. Methods of rodent and human
HSC isolation were developed in the 1980s [46, 47], which
principle is based on collagenase-pronase liver perfusion with
consequent separation of the vitamin A-containing HSC by
density gradient centrifugation in Nycodenz [48]. For further
in vitro activation of HSC and their transdifferentiation into
myofibroblasts, myofibroblast was offered prolonged cultiva-
tion of HSCs on plastic culture plates [49].
Methods that would allow isolation of HSC, which do not
contain vitamin A in cytoplasm, activated myofibroblasts, or
PF, are not yet standardized. We assume that an alternative
method to obtain activated cells, especially myofibroblasts,
could be an explantation tissue culture method. Explantation
tissue culture is a biological technique to organotypically cul-
ture cells from a piece of tissue or organ removed from a plant
or animal [50]. The principle is that cells within the piece
appear to be in stress, excrete various biological substances,
which via paracrine, and autocrine ways will influence on
activation of the tissue fragments cells, on their differentiation
into myofibroblasts with further outgrowth onto the surface of
culture dish. These primary cells can then be later expanded,
cultivated, and transferred into fresh dishes. The major advan-
tage of explantation culture is the maintenance of near in vivo
environment for a short time [50]. For explantational out-
growth from liver are able only the most viable, activated cells
that have the ability to migrate, contractile activity, express α-
SMA—marker of myofibroblasts. Some authors describe dif-
ferent methods of PF isolation, based mainly on the enzymatic
cleaning of the bile duct structures of the liver parenchyma
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fragments [30]. We decided to check whether this method is
applicable without enzymatic digestion of the tissue to de-
crease the enzymatic damage of the cells.
Many biochemical agents are used to stimulate HSC apo-
ptosis in vitro and in vivo, among them are gliotoxin and
curcumin [51].
Gliotoxin is a fungal metabolite of the epipoly-
thiodioxopiperazine class of secondary metabolites. Due to
its antibacterial, antifungal, and antiviral activities, gliotoxin
is thought to be a promising therapeutic agent [51, 52]. It is
known that gliotoxin induces apoptosis of thymocytes, periph-
eral lymphocytes, macrophages, P815 mastocytoma cells, fi-
broblasts line L929, and HSC in vitro, and also cells of the
thymus, spleen, lymphatic nodules of mesentery, and liver
in vivo [53]. Gliotoxin-induced apoptosis of human HSC cul-
ture was demonstrated in 2003 by Young-Oh Kweon and
collegues [54]. However, the mechanism of apoptosis induc-
tion remains unclear. It is known to have diverse biological
activities including proapoptotic effects in vivo and in vitro.
Gliotoxin was shown to induce in the liver:
1) HSC apoptosis and reduced hepatic fibrosis in CCl4 rat
model [52].
2) Might induce adverse effect on other non-parenchymal
cell types.
3) Demonstrates immunosuppressive effects on liver cells
[53].
Similarly, curcumin (or (1E,6E)-1,7-Bis(4-hydroxy-3-
methoxyphenyl)-1,6-heptadiene-3,5-dione) is also an impor-
tant pharmacological agent. It is derived from tropical plant
Curcuma longa, for thousands of years, and is being used as
food spice and for medicinal purposes. Many signaling mole-
cules are modulated by curcumin, such as molecules that ac-
tivate inflammatory process, transcription factors, enzymes,
protein kinases, reductases, carrier proteins, cell survival pro-
teins, drug resistance proteins, adhesion molecules, growth
factors, receptors, cell cycle regulatory proteins, chemokines,
DNA, RNA, and metal ions [55].
The effect of curcumin on the process of fibrogenesis in the
liver has been studied for a long time. Known for its effect on
various cellular processes: adhesion, gene expression, and se-
cretion of various growth factors and mediators [56], it partic-
ipates in angiogenesis and immunomodulation [57]. In addi-
tion, curcumin shows properties of the inhibitor of oxidative
stress and inflammation [58]. There were numerous studies of
the influence of curcumin on cell cycle of various cells lines.
[59]. It is still unknown why the equivalent concentrations of
curcumin induce apoptosis of activated HSC and have no
effect on quiescent HSC and other liver cells such as hepato-
cytes. Lin et al. studied the effect of curcumin on immortalized
cell line HSC-T6 and showed that low concentrations of
curcumin (1.25–10 μM) had no effect on cell survival,
whereas a high concentration of it (20 μM) led to necrosis
[60]. Curcumin provides antioxidative, anti-inflammatory,
antifibrogenic, and antiproliferative effects on HSC.
Interestingly, curcumin can induce apoptosis and prevent ac-
tivation and proliferation of HSC; therewith, it prevents pro-
duction of ECM [61–64].
Worth to note is the study of Baghdasaryan, who investi-
gated the effect of curcumin on the PF and cholangiocytes of
mice Mdr2−/− and showed that curcumin reduces prolifera-
tion and activation of portal fibroblasts via the ERK1/2 signal
pathway [65]. In addition, the efficacy of curcumin in the
treatment of liver fibrosis indicates the observed decrease of
α-SMA and the collagen I synthesis in the liver [66].
Curcumin also leads to suppression of connective tissue
growth factor (CTGF) gene expression in activated HSCs
in vitro [67].
In recent years, another interesting aspects of the
antifibrotic effect of curcumin on HSC were published: (a)
via inhibition of hedgehog signaling in HSC, curcumin regu-
lates metabolism and transdifferentiation of HSC into
myofibroblasts [68]; (b) curcumin inhibits aerobic glycolysis
associated with activation of adenosine monophosphate-
activated protein kinase HSCs [69]; (c) curcumin promotes
apoptosis of activated HSC by inhibiting the expression of
cytokines related to the MyD88 pathway [70]; and d)
curcumin can also induce senescence of HSC [71].
However, the basic effect of curcumin is based on inhibition
of NF-kB-dependent genes expressions [72].
Regarding the role of portal fibroblasts in the synthesis of
extracellular matrix and their great impact in liver fibrosis
development, the study of curcumin and gliotoxin influence
on HSC and PF is important to search for new strategies of
liver fibrosis therapy. PF and HSC start to produce compo-
nents of extracellular matrix after their activation. In most of
the researches, it used quit high concentrations of curcumin
and gliotoxin to induce apoptosis of myofibroblasts. We sup-
pose that it would be better if the cells remained alive and just
reduced their proliferation activity, because these cells also
play an important role in liver regeneration. Thus, using opti-
mal concentrations of curcumin and gliotoxin, it is possible to
inhibit activation of the cells, return them to quiescent phase.
Within this study, we consider to isolate myofibroblasts of
different origins by explantation culture from liver parenchy-
ma and bile duct region and to study the effect of different
concentrations of gliotoxin and curcumin on rat liver
myofibtoblasts in vitro. The aim is to identify optimal concen-
trations of gliotoxin and curcumin to inhibit myofibroblasts.
2 Materials and Methods
The whole work was performed on newborn rats (E4, Rattus
norvegicus, Wistar line, received from Laboratory Animal
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Breeding Facility BPushchino,^ 187 animals). All rats were
handled according to local institutional animal care and use
committee guidelines of Kazan Federal University on the use
of laboratory animals (ethical approval by the Institutional
Animal Care and Use Committee of Kazan State Medical
University N9-2013). Animals were housed in an individually
vented cage system with a 12 h light-dark cycle and received
free access to standard chow and water.
2.1 Preparation and Culture of Hepatic
Myofibroblasts
The hepatic myofibroblasts were isolated by explantation
method. To optimize the technique, we isolated separately
liver parenchyma tissue and region of bile ducts. For this, rats
were sacrificed by decapitation and thereafter under guideline
of binocular microscope (Stemi DV4 Carl Zeiss, Germany)
and using sterile instruments, liver capsule was removed; then,
parenchyma fragments and bile duct region (left, right and
common hepatic ducts) were isolated. Inside the hood, the rest
of parenchymal tissue from bile ducts was mechanically re-
moved. Isolated bile duct regions and liver parenchyma frag-
ments were separately placed in wells of 6-well plates and
smaller 3-mm3 fragments were placed inside the 24-well
plates. Cells were grown in culture medium DMEM supple-
mented by 10% FBS, 200 mM L-Glutamine, and penicillin-
streptomycin (PanEco) [73]. For better adhesion and immo-
bility of the tissue inside the well, the culture medium covered
only a half of the tissue fragment.
On the third day after seeding, the medium was changed
and the tissue fragment (bile duct region and liver parenchyma
fragments, respectively) was removed and embedded follow-
ing a standard technique in paraffin or frozen in Neg-50™
Frozen Section Medium (ThermoScientific). Placed in Neg-
50™, samples were immediately frozen at − 80 °C and was
used to produce thin 5-μm slices on a cryostat microtome-
NM560 Cryo-Star (Carl Zeiss, Germany).
Medium of the growing cells was changed every second
day, and on the 3rd, 5th, 7th, and 12th days, cells from 6-well
plate were collected forWestern blot and flow cytometry anal-
ysis and the cells from 24-well plate were immunocytochem-
ically stained. Part of the cells from 6-well plates after removal
of the tissue fragment (3rd day) had been further cultivated
next 7 days and seeded into 25-cm2 plates at a standard growth
medium. Upon reaching 80%, confluence of the monolayer
cells was passaged.
2.2 Western Blot Analysis
In brief, at the end of the experimental procedure, proteins
from cultured hepatic myofibroblasts were purified and pro-
tein content was determined by the BioRad protein assay
(BioRad, Munich, Germany). After gel electrophoresis and
semi-dry protein transfer, PVDF membranes were incubated
in 10% dry milk solution for 30 min before immunodetection
was performed using antibodies against α-SMA (mAb,
1:100), IkBα (rAb, 1:100), NF-kB (rAb, 1:500) or β-actin
(mAb, 1:2000), respectively (Table 1). For detection of prima-
ry antibodies, blots were incubated with horseradish
peroxidase-coupled anti-mouse or anti-rabbit IgG antibody
(Sigma Aldrich) diluted 1:5000 at room temperature for 2 h,
respectively. Blots were washed again and peroxidase activity
was detected using chemiluminescent protein detection kit
Amersham ™ ECL ™ Prime Western Blotting Detection
Reagent (GE Healthcare Bio-Sciences AB). For image acqui-
sition and densitometric analysis, we used the ChemiDoc™
XRS + System (Bio-Rad, Singapore).
2.3 Immunocytochemistry
and Immunohistochemistry Analysis
Immunocytochemistry analysis was performed by microsco-
py using AxioOberver.Z1 (Carl Zeiss, Germany). On the 3rd,
5th, 7th, and 12th days, hepatic myofibroblasts cultured on
glass cover slips (Ø 12 mm) were fixed with paraformalde-
hyde (4%, 5 min), washed thrice with TBS, and incubated in
TBS containing 0.1% Triton X-100 for 10 min at room tem-
perature. Thereafter, cells were incubated for 1 h at room
temperature using primary antibodies listed in Table 1. Cells
were washed extensively and proceeded by post primary
block and polymer of system Novolink (Novocastra, UK)
for all antibodies and streptavidin-biotin CSA system (Dako,
Denmark) for C-kit antibody. Visualization of the staining was
performed with a colorimetric substrate 3-Amino-9-
ethylcarbazole (AEC, Sigma Aldrich, USA). Nuclei were
counterstained with hematoxylin (Novocastra, UK) according
to standard procedures.
In the case of immunohistochemistry, the steps of the stain-
ing procedure were the same, except two steps: first step was
deparaffinization by consequent incubation of the slices with
toluene and absolute ethanol and thereafter for retrieval of
antigens, the slices were boiled in citrate buffer for 30 min.
2.4 Flow Cytometry Analysis
Primary culture of hepatic myofibroblast on the seventh day
was collected for the study by flow cytometry. To detect in-
tracellular antigens, the cells were fixed in a commercial re-
agent CellFix (Becton Dickenson) on the basis of formalde-
hyde for 30min at 4 °C; membrane permeability was provided
by incubation in 0.1% solution of Tween-20 in PBS for
10 min. For staining of membrane antigens, permeability step
was skipped and the fixation of the cells was carried out after
the staining procedure (postfixation). The results were ana-
lyzed on a flow cytometer Guava easyCyte 8HT (Millipore).
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2.5 Curcumin and Gliotoxin Incubation/Processing
and Detection of Apoptosis
On the basis of published data about the effects of different
concentrations of curcumin and gliotoxin on HSC, our obser-
vations selected three concentrations of curcumin (100, 50,
and 30 μM) and gliotoxin (0.25, 0.1, and 0.05 μM) for pro-
cessing the cell culture of hepatic myofibroblasts [74].
Upon forming a monolayer, the hepatic myofibroblasts
grown on 6-well plate were incubated for 24 h with curcumin
or gliotoxin at chosen concentrations. Thereafter, the superna-
tant was collected, centrifuged for 5 min at 500×g to gather
swimming cells. The remaining cells were trypsinized, col-
lected, and centrifuged for 5 min at 500×g. The first and
second cellular pellets were combined and washed twice with
1× Binding buffer and stained with Annexin-V FITC PI
(Sigma APOF 20TST, USA) according to the manufacturer’s
instructions. After that, we calculated the percentage of cells
in different states using the flow cytometer Guava easyCyte
8HT (Millipore).
2.6 Study of Cell Index
Technology of xCELLigence Real-Time Cell Analyzer
(Roche, Germany) is based on the use of microelectronic sen-
sors, integrated into the bottom of special culture plates. With
a predetermined frequency, the impedance is measured be-
tween the sensor electrodes that gives us the information about
the density and attachment of the cells, having dielectric
properties. We programmed the frequency of measurements
to every 15 min during 4 days. Before starting the experiment,
it was added 100 μl of culture medium in each well of the
special plate and set the background value (subtracting the
influence of culture medium/media containing the test sub-
stance on the impedance value) of the device. Then, seeded
5000 cells per well. After 24 h, the curcumin and gliotoxin
respectively were added in chosen concentrations.
3 Results and Discussion
Hepatic myofibroblasts were isolated from two different liver
fragments—liver parenchyma and bile duct region; they ap-
peared to be two different myofibroblast cultures.
Myofibroblasts from Liver Parenchyma The first explantational
outgrowth of the cells from liver parenchyma fragments was
observed on the third day after seeding (Fig. 1a). The morphol-
ogy of these cells resembled the morphology of HSC—large
cells with numerous processes (Fig. 1b). Myofibroblast nature
was confirmed by staining with the antibody against their mark-
er—α-SMA that was present in phenotype of all the cells. The
expression of α-SMA gradually increased, indicating further
constant transformation of the isolated cells into myofibroblasts
(Fig. 1c)—cells capable of contraction and migration [75].
Performing the immunocytochemical staining on the 3rd, 5th,
7th, and 12th days of their growth, there was determined strong
expression of the rat’s HSC marker desmin (Fig. 1d) at all
Table 1 List of antibodies
Name of antigen Company, cat. no., dilution
Desmin—protein of intermediate filament of muscle cells cytoskeleton, marker of HSC Santa Cruz (SC14026), 1:100, Dako (M076001), 1:30
α-SMA—α-smooth muscle actin, marker of myofibroblasts, and smooth muscle cells Santa Cruz (SC130616), 1:100, Dako (M0851), 1:50
Cytokeratin-18 (CK-18)—protein of intermediate filament of epithelial
cell cytoskeleton (hepatocytes, cholangiocytes)
Dako (M7010), 1:20
Cytokeratin-19 (CK-19)—protein of intermediate filament of epithelial
cell cytoskeleton (cholangiocytes, hepatoblasts, oval cells)
Dako (M0888), 1:20
Thy-1 (CD90)—membrane surface protein, one of the stem cell markers Abcam (ab225), ICC 1:200
C-kit (CD117)—stem cells growth factor receptor Novocastra (T595), 1:400
NF-kBp65—universal transcription factor that controls expression of the
immune response genes, apoptosis, and cell cycle
Santa Cruse (SC372), ICC 1:50, WB 1:500
IkBα—inhibitor protein of NF-kB Santa Cruse (SC 371), ICC, WB 1:50
MMP-9—matrix metalloproteinase 9, one of the enzymes that remodel ECM Abcam (ab7299), 1:50
MMP-3—matrix metalloproteinase 9, degrade collagen II, III, IV, IX и X
types, proteoglycans, fibronectin and elastin, activate other MMPs, such
as MMP-1, MMP-7 andММP-9
Santa Cruse (SC 6839), 1:50
Caspase-7—enzyme that plays central role in cellular apoptosis Santa Cruse (SC 6138), 1:50
Albumin—marker of differentiated hepatocytes Santa Cruse (SC 50536), 1:50
α-Fetoprotein (α-FP)—one of the hepatoblast proteins Santa Cruse (SC 8108), 1:50
CD45—marker of blood cells (leukocytes) Santa Cruse (SC 25590), 1:50
β-actin—protein of cells cytoskeleton, provides structure and integrity of the cells Sigma Aldrich (Mab-A2228), WB 1:2000
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stages of the experiment, which allows us to assume that the
migrated cells were mostly activated HSC and only a few
desmin-negative cells could be PF. Another marker expressed
by every cell was C-kit—a marker of progenitor and stem cells
(Fig. 1e), sustaining that these migrated cells had features of
activated progenitor cells. To exclude the epithelial origin of the
explanted cells, we checked expression of CK-18 (Fig. 1f) and
CK-19 (data not shown). Expression of these antigens like ex-
pression of α-FP (Fig. 1g) and albumin (Fig. 1h) was not pres-
ent that meant the absence of any epithelial cell admixture; there
were neither hepatocytes nor cholangiocytes. To check the he-
matopoietic origin of the cells, we stained cell culture with
antibodies against CD45 (Fig. 1i); this antigen was not
expressed too, indicating an absence of blood cells in the ex-
perimental culture. Lack of expression of MMP-3 (Fig. 1j) and
caspase-7 (data not shown) meant that the cells actively prolif-
erated and there was no cell apoptosis.
It is worth to note that the high activity of the cells could be
estimated by staining of cell culture with antibodies against
NF-kB (Fig. 1k) and IkBα (Fig. 1l). We have observed a
steady nuclear and cytoplasmic expression pattern in all cells
and throughout the whole experiment. The expression of NF-
kB mainly in the nucleus indicated a permanent activation of
this transcription factor. This fact was confirmation of activat-
ed state of HSC, their transformation into myofibroblasts, and
indirect confirmation of their fibrogenic features.
High and stable expression of NF-kB, IkBα, and α-SMA
proteins was also confirmed by Western blot (Fig. 2).
To distinguish whether the explanted cells were HSC or PF,
we stained the histological slices of the paraffin-embedded
tissue on the third day after seeding with antibodies against
desmin. We observed necrotic changes in the center of the
fragment, while at the periphery of the tissue, it was noted a
large number of desmin+ HSC (Fig. 3).
Regarding these results, we can make the following con-
clusions. This explantation method from liver parenchyma
fragment allows obtaining culture of rat liver myofibroblasts.
By analyzing the phenotype of these cells and histological
slices of the liver fragments, we can propose that derived
myofibroblasts are the result of desmin+ HSC transformation
mostly, but not PF (desmin-). HSCs are relatively more active,
viable, and able to explant in compare to PF.
Fig. 1 Cell cultures of rat liver
fragments: a during the cell
isolation of the fragments liver,
3rd day; b monolayer
myofibroblasts, 12-day culture; c
α-SMA expression, 7 days; d
desmin expression, 3 days; eC-kit
expression, 7 days; f CK-18
expression, 7 days; g α-FP, × 10,
12 days; h albumin, × 10,
12 days; i CD45, × 20, 7 days; j
MMP3, × 10, 12 days; k NF-kB,
p65 isoform expression, 12 days; l
IkBα expression, 7 days.
Magnification: a, g, h, j, l × 10; b,
d, f, i, k × 20; c, e × 40
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The culture of myofibroblasts was characterized by high
activity of the transcription factor NF-κB and its inhibitor
IκBα that corresponds to high expression levels of these sub-
stances by activated HSC during liver fibrosis [76]. The ob-
served in vitro activation process resembles the changes that
occur with HSC and PF in vivo in the case of liver fibrosis.
Thus, the model of explanted liver cells can be used in the
preparation of liver myofibroblasts to conduct further experi-
ments on inhibition of NF-κB and the study of the processes
that lead to fibrosis of the liver. Understanding the origin of
myofibroblasts and biology opens up new possibilities for
finding necessary therapy.
Myofibroblasts from Bile Duct Region It is thought that portal
fibroblasts, like HSC, in the case of chronic liver damage
differentiate into myofibroblasts, expressing α-SMA. This
could be modeled in vitro by cultivation of portal fibroblasts
on cell culture dish or glass cover slips [77]. In our work,
in vitro damage of the liver was mechanical damage during
bile duct extraction. Under an operational microscope, we
removed the surrounding liver parenchyma and placed in cul-
ture medium the bile duct regions that is together with portal
vein and hepatic artery form the portal tracts.
The cellular explantational outgrowth was visualized on
the third day of cultivation, similar to the previous group with
explantational outgrowth of myofibroblasts from liver paren-
chyma. The cell population was heterogeneous: some of them
had cuboidal, some—spindle-shaped morphology. To study
the phenotype of the explanted cells, we performed flow cy-
tometry and the results showed that there were only 7% of
desmin+ cells, indicating that the bile ducts were properly
purified from the liver parenchyma and there were a minimum
of the HSC-originated myofibroblasts in the culture (Fig. 4b).
This is also evidenced by immunocytochemistry for desmin in
primary cell cultures and further in cultures of the first and
second passages where only single desmin+ cells were deter-
mined (Fig. 5a–c).
Flow cytometry combined with Thy-1 staining showed
that about 81% of the primary culture cells were Thy-1+
(Figs. 4c; 5d, e; 6b). In a number of studies, Thy-1 is de-
scribed as a marker of bile duct cells and progenitor cells,
while other researchers believe that the population of Thy-
1+ is heterogeneous. There is also a report about the expres-
sion of Thy-1+ mesenchymal stem cell such markers as α-
SMA and desmin [78]. Our study confirmed that PF were
Thy-1+ cells, while hepatocytes, HSC, and liver macro-
phages did not express this marker. Thus, Thy-1 can be
called one of the surface markers for the identification of
the PF in vivo and in vitro [79].
At the 7th day of cultivation, 73% of the primary
myofibroblast culture cells expressed the marker of
myofibroblasts—α-SMA (Figs. 4a, 5f). Thereafter, the cells
of the first and second passages did not express α-SMA, prob-
ably they transformed back into fibroblasts (Fig. 5g).
Interestingly, by prolonged cultivation (passage 4), these cells
resembled fibroblast morphology and phenotype, but later,
some of the cells started to express α-SMA again (Fig. 6a),
indicating repeated myofibroblast transformation of fibroblasts.
These data confirm previously theorized possibility of fibro-
blasts to transdifferentiate into myofibroblasts [80]. The ab-
sence of epithelial markers (CK-18 and CK-19) confirmed that
obtained cells were non-epithelial origin (Fig. 5h, i). Between
these cells, there were no mature hepatocytes, they were
albumin- and α-fetoprotein-negative. Thus, the cells, explanted
from bile duct region fragments, weremyofibroblasts andmost-
ly had PF origin and only few of the cells were activated HSC.
Fig. 2 Immunoblotting cell lysate proteins, obtained from the cell
cultures on different stages of cultivation: M—molecular weight marker
proteins; 5, 7, 12—duration of cell culture in vitro, days
Fig. 3 Rat liver. Immunohistochemical reaction with antibodies to
desmin, the third day of cultivation in vitro, × 40
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Intermediate Conclusion In this model, we saw activation of
fibroblasts, mostly PF, with further outgrowth from hepatic bile
duct fragments. The presence of the 7% of desmin-positive
myofibroblasts meant the presence of only 7% myofibroblast
population, originating fromHSC. According to the absence of
epithelial markers (CK18, CK-19) and markers of mature
Fig. 5 Culture of cells derived
from the bile duct region: a
primary culture, the 7th day; b, h,
i the culture of the first passage,
the 5th day; c the culture of the
second passage, the 5th day; d, f
primary culture, the 12th day; e, g
the culture of the second passage,
the 7th day; a–c expression of
desmin; d, e expression of Thy-1;
f, g expression of α-SMA; h
expression of CK-19; i expression
of CK-18. Immunocytochemical
reaction, the nuclei counterstained
with hematoxylin. Magnification:
a-d, f, g, i—× 10, e—× 20, h—×
40
Fig. 4 Flow cytometry.
Phenotype of primary culture
cells isolated from the bile duct
region: R1—cells expressing the
marker; R2—cells not expressing
the marker; R3—cells expressing
Thy-1
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hepatic cells (albumin and α-FP), we suggest that there were
no mature parenchymal cell contamination.
As a result, we can propose this tissue culture explantation
model as a model for activated myofibroblast isolation. The
region of the liver fragment allows to isolate myofibroblasts of
different origins: from liver parenchyma fragment outgrow
mostly myofibroblasts from activated HSC, from bile duct
region—myofibroblasts from PF.
Other authors describe various methods for isolation of PF
culture; their principle is based on enzymatic treatment of the
bile duct structures from hepatic parenchyma [30].
Explantational method has several advantages in compare to
these techniques: (1) simpler; (2) needs no additional sub-
stances, thus much cheaper; and (3) no enzymatic digestion of
the tissue that damages the cells including PF. The disadvantage
of explantational method is that this method does not allow to
Fig. 7 The effect of curcumin on
necrosis and apoptosis of portal
myofibroblasts. Curcumin was
added to the cell culture at
concentrations of 100, 50, and
30 μM. After 24 h of incubation,
the percentage of apoptosis and
necrosis of the cells was
determined by flow cytometry
Fig. 6 The culture of cells
isolated from the bile duct
regions: a the culture of the 5th
passage, the expression of α-
SMA; b the culture of the 9th
passage, expression of Thy-1.
Nuclei visualization by DAPI
staining (blue). Fluorescence
microscopy
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isolate absolutely pure culture of portal myofibroblasts, but by
liver fibrosis, there is activation of myofibroblasts from both
origin (HSC and PF) and in this experiment, we can skip this
disadvantage. To ourmind, it is even better to study the effect of
various substances on mixture of different myofibroblasts; it
models the natural reaction of the liver cells.
In most of the clinical cases, liver fibrosis starts near the
main portal tract or intrahepatic bile ducts with activation of
myofibroblasts from PF, that is why we chose the second
model to isolate the culture of PF by seeding the fragments
of the bile duct region.
So far, one of the modern strategies of liver fibrosis treat-
ment is prevention of myofibroblast activation; in our next
experiments, we studied the influence of curcumin and
gliotoxin on myofibroblast culture. Curcumin and gliotoxin
are known to be inhibitors of myofibroblast activation and to
induce apoptosis of myofibroblasts.
3.1 Analysis of the Effect of Curcumin on Rat Liver
Portal Myofibroblast Culture in Various
Concentrations
Performing the flow cytometry, we analyzed the quantity of the
portal myofibroblasts that were in necrotic and apoptotic phase
after incubation with curcumin. We got the following results
(Fig. 7): at the highest concentration of curcumin (100 μM),
cell necrosis count was greater (35.86%) than the cell apoptosis
Fig. 8 Visualization of rat liver
cells (which are in necrotic and
apoptotic phases) incubated with
various concentrations of
curcumin (30, 50, 100 μM) using
fluorescence microscopy (× 20).
Cells in early apoptotic phase are
stained with a green dye only
(AnnexinV-FITC) and cells in
necrotic phase are stained with
green and red dye (Propidium
Iodide). Living cells are not
stained
Fig. 9 The cell index
(proliferation activity) of portal
fibroblasts after curcumin
exposure in various




BioNanoSci. (2018) 8:522–536 531
count (14.41%). At a lower concentration (50 μM), necrosis
count was reduced to 10.96% and apoptosis count was two
times reduced (6.72%). At the lowest curcumin concentration
(30 μM), we observed the lowest necrosis count (7.64%), but
interestingly, the apoptosis count increased (9.54%) and was
higher than at 30 μM curcumin concentration.
The same results were obtained by immunocytochemical
staining and study of the cell index. The highest concentra-
tions of curcumin (100 μM) had the most toxic effect on cells.
After, an initial period of adaptation of the cells to the sub-
stance began their apoptosis (Annexin-V+/PI-), and then, the
cells were in late apoptosis/necrosis stage (Annexin-V+/PI+),
which is reflected on the fluorescent photographs (Fig. 8m–p)
and in descending curve of cell index showing a reduction of
cell proliferation (Fig. 9). To the medium (50 μM) concentra-
tions of curcumin cells adapted well, signs of early apoptosis
were observed (Annexin-V+/PI-); only a few cells were in the
stage of late apoptosis/necrosis (Annexin-V+/PI+) (Fig. 8i–l).
Then, the cell index curve appeared on the plateau phase;
however, these values were below the control numbers (no
added compounds) (Fig. 9). This concentration can be consid-
ered as the most effective, as the cells retain the ability to
proliferate, although at a lower level. It is seen that the growth
of cells relative to cells in the control group decreased by
about 50%. When exposed to low concentrations of curcumin
(30 μM), only a few cells underwent apoptosis (Fig. 8e–h) and
cell index was almost the same without changes (Fig. 9). It is
known that curcumin blocks the expression of a broad spec-
trum of genes (PPAR-γ, α1-collagen, α-SMA, CTGF, recep-
tor of TGF-β, PDGF, EGF), which indicates that curcumin
acts on many signaling pathways, including, perhaps, the ac-
tivation pathway of inflammation and fibrogenesis [81].
The study of the curcumin effect on cell growth of various
cell lines in vitro indicates that curcumin has an effect on cells
in a wide range of micro- and millimolar concentrations. As a
result of its action, there is induced apoptosis and decreased
generation of reactive oxygen species [59]. It is known that
curcumin has a strong antioxidant effect, even stronger than
vitamins C and E [82–85]. Since the lowest concentration of
30 μM curcumin showed almost no effect on the cell index,
this concentration may be offered for use in vivo as an anti-
oxidant. Depending on the concentration, curcumin is capable
to induce apoptosis and necrosis of PF in vitro. We assume
that the highest allowable concentration of curcumin that can
Fig. 10 The number of PF with
apoptosis and necrosis after
incubation with gliotoxin in
various concentrations (0.05, 0.1,
0.25 μM). AnnexinV-FITC—a
marker of apoptosis; PI—a
marker of necrosis. Flow
cytometry
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be used to suppress activated PF and will have antifibrotic
effect in vivo is 50 μM. However, the mechanism of its hepa-
toprotective action in vivo is not yet fully disclosed [86].
3.2 Analysis of the Effect of Gliotoxin on Rat Liver Cell
Cultures in Various Concentrations
Incubation of PF culture with gliotoxin leads to changes of
cell morphology—they became rounded, lost intercellular
contacts, detached from the culture of plastic, and swam in
the suspension; some of them exposed to necrosis (Figs. 10
and 11). These gliotoxin effects were due to the fact that
gliotoxin inhibits the expression of surface adhesion markers,
such as VCAM, ICAM, and E-selectin, and is involved in the
reorganization of the cytoskeleton (e.g., actin) [87].
In the first 24 h, 0.05 μM gliotoxin had no effect on the
cells. Cells were subjected for a short period of time to
apoptosis (Figs. 10 and 11), but then recovered and after
72 h, their growth cell index was even higher than the one
of control culture cells (Fig. 12). Incubation of PF culture
with 0.1 μM gliotoxin induced apoptosis of PF and partially
their necrosis (Figs. 10 and 11) and further increase of cell
culture growth index was not observed (Fig. 12). Thus,
gliotoxin in concentration of 0.1 μM inhibits the PF prolif-
eration (Fig. 12).
The concentration of 0.25 μM was too toxic and causes
necrosis of PF (Fig. 10, 11, and 12). In compare to curcumin,
Fig. 11 Visualization of rat PF
(which are in necrotic and
apoptotic phases) incubated with
various concentrations of
gliotoxin (0.05, 0.1, 0.25 μM)
using fluorescence microscopy
(× 20). Cells in early apoptotic
phase are stained with a green dye
only (AnnexinV-FITC) and cells
in necrotic phase are stained with
green and red dye (Propidium
Iodide). Living cells are not
stained
Fig. 12 The cell index
(proliferation activity) of portal
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gliotoxin is more toxic for PF. Thus, by incubation of PF with
gliotoxin in concentration of 0.25 μM, 63.65% of the cells
died and 31.95% were apoptotic, alive remained only 3.32%
of the cells (Fig. 10). With decrease of gliotoxin concentration
(0.1 μM), the percentage of the dead and apoptotic cells de-
creased (49.86 and 24.90%, respectively), and the number of
living cells increased—22.66% (Fig. 10). The smallest of the
selected concentrations of gliotoxin (0.05 μM) did not lead to
immediate cell death (necrosis 8.82%), but 15.04% of the cells
were in apoptotic phase, which is almost eight times higher
than the spontaneous apoptosis in the control cell culture
(1.92%). The number of alive cells was determined to be
76.14% (Fig. 10). Effects of gliotoxin on cultured PF were
also examined by inverted fluorescence microscopy after
staining with AnnexinV-FITC and PI (Fig. 11).
Based on our results, the 0.1 μM concentration of gliotoxin
is not toxic for the cells, but still it reduces the proliferative
activity of PF and can have a significant effect onmyofibroblast
culture.
4 Conclusion
Explantational cell growth is an alternative method for
myofibroblast isolation. It is important to note that this method
allows to isolate myofibroblasts of different hepatic origins:
from liver parenchyma outgrow myofibroblasts from activat-
ed HSC, from bile duct region fragments—myofibroblasts
from PF. To study the ways of prevention of myofibroblast
activation and induction of their apoptosis, there were two
substances chosen—curcumin and gliotoxin. The effect of
these substances on myofibroblast apoptosis has been shown
to be concentration-dependent. Based on abovementioned re-
sults, the optimal concentration of curcumin is 50 μM and
concentration of gliotoxin—0.1 μM. At these concentrations,
we observed suppression of hepatic myofibroblast activation
and inhibition of their proliferation, that means, that even after
their treatment with gliotoxin and curcumin, cells will be able
to participate in liver regeneration. The results extend the cur-
rent knowledge of the myofibroblasts within the liver and
open up new possibilities for biologically active substances
(curcumin and gliotoxin) to influence on their activity and
fibrogenic potential.
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